The fight against gastric cancer – the IARC Working Group report

Herrero, Rolando; Park, Jin Young; Forman, David

doi:10.1016/j.bpg.2014.10.003

Cited by 155 publications

(124 citation statements)

References 2 publications

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…On the other hand, the prevalence of individuals with normal gastric mucosa was high in all groups of patients, even in the group with a severely decreased PG level; 61% of patients were without high-risk lesions, indicating a low specificity of the test. However, the high proportion of false-positive test results could be also explained by other causes that could affect PG levels indicated in other studies [3,5,23,24,25]. Nevertheless, the low specificity of the test should be kept in mind while interpreting patients' data.…”

Section: Discussionmentioning

confidence: 97%

Pepsinogen Test for the Evaluation of Precancerous Changes in Gastric Mucosa: a Population-Based Study

Sjomina

Pavlova

Daugule

et al. 2018

JGLD

View full text Add to dashboard Cite

Aims: The aim of the study was to evaluate the rationale of blood pepsinogen (PG) testing in population based screening settings.Methods: Participants from a cross-sectional population-based study of cardiovascular risk factors in Latvia were invited to participate in the current study. Pepsinogen I and II were measured in blood samples taken during the initial study and at follow-up; upper gastrointestinal endoscopy was performed. There were three groups of patients: with moderately decreased (PG I< 70 ng/ml and PG I/PG II ratio < 3), with strongly decreased (PG I< 30 ng/ml and PG I/PG II ratio < 2), and with normal PG level. Biopsy with H. pylori detection was performed (updated Sydney system).Results: Results from 259 patients were analyzed. Pepsinogens were decreased in 133 (51.4%), H. pylori was positive in 177 (66.0%) cases. Mean age was significantly lower in patients with normal compared to strongly decreased PG level group (52.8 vs. 64.1 years, p<0.001). Prevalence of severe corpus atrophy was higher in the strongly decreased compared to the normal PG test group: 7.0% vs. 0%; the same tendency was noted in the distribution of OLGA stages III-IV – 10.5% and 0.0%, OLGIM stages III-IV – 3.5% and 0%, and low-grade dysplasia – 15.8% and 2.4% (p<0.05). Two cases of gastric cancer were found; both presented decreased PG levels. A strong association between H. pylori eradication and PG ratio dynamics was found (p<0.05).Conclusions: All high-risk lesions were found in the decreased PG test groups; two cancer cases were revealed.However, PG demonstrated low specificity and low value of repeated testing. The value of PG as a sole test for gastric cancer risk is limited.

show abstract

Section: Discussionmentioning

confidence: 97%

Pepsinogen Test for the Evaluation of Precancerous Changes in Gastric Mucosa: a Population-Based Study

Sjomina

Pavlova

Daugule

et al. 2018

JGLD

View full text Add to dashboard Cite

show abstract

“…For example, gastric cancer is one of the most frequently diagnosed cancers, and is the third leading cancer-related cause of death with more than 720,000 deaths per year worldwide [1]. CRC is the third leading cancer among men, and the second among woman globally, with a significant increase in its incidence in East Asian countries [2].…”

Section: Introductionmentioning

confidence: 99%

Additional Benefits of Routine Drugs on Gastrointestinal Cancer: Statins, Metformin, and Proton Pump Inhibitors

Joo

Park

Chun

2017

Dig Dis

View full text Add to dashboard Cite

Background: Commonly used medications including statins, metformin, and proton pump inhibitors (PPIs) effectively reduce the risk of esophageal, gastric, and colorectal cancer (CRC). Summary: A number of observational studies and meta-analyses have shown that long-term statin use significantly reduces the incidence of gastrointestinal (GI) cancer. Moreover, statin use after GI cancer diagnosis has been significantly associated with better prognosis in large-scale cohort studies. Metformin was rigorously evaluated in a population-based study and meta-analysis, and was found to have an unexpected benefit in the prevention and prolonged survival of CRC patients with type 2 diabetes mellitus. In contrast, few studies have demonstrated the chemopreventive effect of metformin for esophageal and gastric cancer. Recent observational studies have demonstrated that PPIs effectively reduce the progression of nondysplastic Barrett's esophagus into esophageal adenocarcinoma in a dose-dependent manner. However, the association between chronic PPI use and CRC or gastric cancer risk is still controversial. It was expected that these 3 routinely used medicines would show a synergistic effect with conventional systemic chemotherapy in advanced GI cancers. However, recent phase III studies failed to show significantly better outcomes. Key Messages: Further studies are needed to identify “additional” anticancer effects of these commonly used medicines.

show abstract

“…(24) . La investigación determinó una seroprevalencia general de 63.6% para los pobladores de la ciudad de Lima en Perú; este valor de seroprevalencia es cercana a lo reportado en México con un 52.2% (8), y 52.9% en Corea (7) , pero menor comparado con la seroprevalencia determinada en China (83.4%) (6) y reportado en Etiopía (83.3%) (11) .En un estudio en nuestro medio, Ramírez Ramos y Col, luego de evaluar 1815 endoscopías realizadas entre 1985 y el 2002, en pacientes de nivel socioeconómico medio y alto, encontró una disminución significativa de la prevalencia de la infección del estómago por H. pylori: 83,3% en 1985, 75,1% en 1990, 65,0% en 1996, y 58,7% en el 2002 (26) .…”

Section: Discussionunclassified

“…El grupo de trabajo consideró que una enorme carga de enfermedades, no se espera que disminuya las próximas décadas, para lo cual se requiere una acción decisiva de salud pública que incluya el cáncer gástrico en los programas de control del cáncer (16) .…”

Section: Introductionunclassified

Perfil de valores de estudiantes de carreras de salud del sur de Chile

et al. 2017

View full text Add to dashboard Cite

RESUMENObjetivo: Conocer la seroprevalencia de infección por Helicobacter pylori en población adulta de Lima, Perú 2017. Materiales y métodos: Estudio descriptivo, prospectivo, transversal. Población conformada por voluntarios mayores de 18 años, de ambos sexos, con o sin molestias gastroenterológicas generales. Campaña de despistaje realizada en los distritos de Magdalena y Chorrillos de la ciudad de Lima, Perú en el mes de enero del 2017. Para el diagnóstico se utilizó la prueba rápida OnSite H. pylori Ab Combo Rapid Test CE de CTK Biotech. Resultados: Se evaluó a 140 pacientes, edad media 36.6 años, 22.1% de sexo masculino y 77.9% de sexo femenino. La seroprevalencia para Helicobacter pylori fue 63.6%. Conclusiones: Nosotros concluimos que la infección por Helicobacter pylori es frecuente en el área de la ciudad de Lima, sin diferencia entre género y edad.Palabras clave: Helicobacter pylori; cáncer de estómago; gastritis; úlcera gástrica. Seroprevalence of Helicobacter pylori infection among an adult population of Lima, Peru 2017ABSTRACT Objective: To know the seroprevalence of Helicobacter pylori infection among an adult population of Lima, Peru 2017. Materials and methods: Descriptive, prospective, cross-sectional study. Population of volunteers older than 18 years, of both sexes, with or without general gastrointestinal discomfort. A screening campaign was carried out in the districts of Magdalena and Chorrillos in the city of Lima, Peru, in January 2017. For the diagnosis, CTK Biotech's OnSite H. pylori Ab Combo Rapid Test CE was used. Results: One hundred forty (140) patients were evaluated, with a mean age of 36.6 years old, being 22.1% male and 77.9% female. The seroprevalence of Helicobacter pylori infection was 63.6%. Conclusions: We conclude that Helicobacter pylori infection is common in the city of Lima, with no difference between gender and age.

show abstract

The fight against gastric cancer – the IARC Working Group report

Cited by 155 publications

References 2 publications

Pepsinogen Test for the Evaluation of Precancerous Changes in Gastric Mucosa: a Population-Based Study

Pepsinogen Test for the Evaluation of Precancerous Changes in Gastric Mucosa: a Population-Based Study

Additional Benefits of Routine Drugs on Gastrointestinal Cancer: Statins, Metformin, and Proton Pump Inhibitors

Perfil de valores de estudiantes de carreras de salud del sur de Chile

Contact Info

Product

Resources

About